

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics
科笛集团

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2487)

VOLUNTARY ANNOUNCEMENT

**A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY OBTAINED
THE “DRUG MANUFACTURING CERTIFICATE” ISSUED BY THE
JIANGSU MEDICAL PRODUCTS ADMINISTRATION**

This announcement is made by Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that Cutia Therapeutics (Wuxi) Co., Ltd. (科笛生物醫藥(無錫)有限公司) (“**Cutia Wuxi**”), a wholly-owned subsidiary of the Company, has obtained the “Drug Manufacturing Certificate” (藥品生產許可證) (the “**Drug Manufacturing Certificate**”) issued by the Jiangsu Medical Products Administration (江蘇省藥品監督管理局). Details of the Drug Manufacturing Certificate are set out below:

I. MAIN INFORMATION OF THE DRUG MANUFACTURING CERTIFICATE

Company Name: Cutia Therapeutics (Wuxi) Co., Ltd.

Registered And Manufacturing Address: 27-2, 27-4 Hongyun South Road, Hongshan Street, Xinwu District, Wuxi, Jiangsu Province

Manufacturing Scope: Cream and foam

Certificate Number: SU20240003 (蘇20240003)

Valid Until: 31 March 2029

Issuing Authority: Jiangsu Medical Products Administration

Obtaining the Drug Manufacturing Certificate by Cutia Wuxi is expected to play a long-term constructive role in production capacity expansion and market development of the Company, thus laying the foundation for subsequent commercialisation of the product candidates.

Warning: Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 30 April 2024

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.